Yeji

$NUVL

Nuvalent, Inc.

Runway:42 mo
NasdaqMarket cap: —CIK 0001861560

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD~ low confidence
$NUVLNuvalent, Inc.
“On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.”

Drug pipeline

zidesamtinib
tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer
NVL-520
Non Small Cell Lung Cancer
Neladalkib (NVL-655)
Non-small Cell Lung Cancer
NVL-655
Non Small Cell Lung Cancer
Zidesamtinib (NVL-520)
Locally Advanced Solid Tumor
NVL-330
Locally Advanced Solid Tumor

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06765109Neladalkib (NVL-655)Phase 3Recruiting2029-12-01
NCT05118789Zidesamtinib (NVL-520)Phase 2Recruiting2027-12-31
NCT05384626Neladalkib (NVL-655)Phase 2Recruiting2027-12-01
NCT06521554NVL-330Phase 1Recruiting2027-01-01
NCT06797362NVL-520—Available—
NCT06834074NVL-655—Available—

Recent catalysts

NDA/BLA filedSep 22, 2025· 257d ago
$NUVLNuvalent, Inc.
zidesamtinib · tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer
“On September 22, 2025, Nuvalent, Inc. announced the completion of its New Drug Application submission to the U.S. Food and Drug Administration for zidesamtinib in tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer.”